{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:39:39Z","timestamp":1790667579564,"version":"4.1.0"},"reference-count":66,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.2967\/jnumed.120.259697","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:21:02Z","timestamp":1630578062000},"page":"1192-1199","source":"Crossref","is-referenced-by-count":32,"title":["Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma"],"prefix":"10.2967","volume":"62","author":[{"given":"Jorge A.","family":"Carrasquillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pryma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"2021092307551480000_62.9.1192.1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","article-title":"Incidence of pheochromocytoma and sympathetic paraganglioma in The Netherlands: a nationwide study and systematic review","volume":"51","author":"Berends","year":"2018","journal-title":"Eur J Intern Med."},{"key":"2021092307551480000_62.9.1192.2","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9484-5"},{"key":"2021092307551480000_62.9.1192.3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2967\/jnumed.120.259689","article-title":"Imaging of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J Nucl Med."},{"key":"2021092307551480000_62.9.1192.4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: an National Institutes of Health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract."},{"key":"2021092307551480000_62.9.1192.5","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1353.053"},{"key":"2021092307551480000_62.9.1192.6","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2021092307551480000_62.9.1192.7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer."},{"key":"2021092307551480000_62.9.1192.8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1907"},{"key":"2021092307551480000_62.9.1192.9","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12542"},{"key":"2021092307551480000_62.9.1192.10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br J Cancer."},{"key":"2021092307551480000_62.9.1192.11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fonc.2014.00166","article-title":"External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma","volume":"4","author":"Vogel","year":"2014","journal-title":"Front Oncol."},{"key":"2021092307551480000_62.9.1192.12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1720"},{"key":"2021092307551480000_62.9.1192.13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The challenges of treating paraganglioma patients with 177Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols","volume":"49","author":"Makis","year":"2015","journal-title":"Nucl Med Mol Imaging."},{"key":"2021092307551480000_62.9.1192.14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol."},{"key":"2021092307551480000_62.9.1192.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3496"},{"key":"2021092307551480000_62.9.1192.16","first-page":"349","article-title":"Radiolabeled adrenergic neuron-blocking agents - adrenomedullary imaging with [131I]iodobenzylguanidine","volume":"21","author":"Wieland","year":"1980","journal-title":"J Nucl Med."},{"key":"2021092307551480000_62.9.1192.17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jso.23196","article-title":"Radionuclide therapy of adrenal tumors","volume":"106","author":"Carrasquillo","year":"2012","journal-title":"J Surg Oncol."},{"key":"2021092307551480000_62.9.1192.18","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00052-K"},{"key":"2021092307551480000_62.9.1192.19","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2009.0695"},{"key":"2021092307551480000_62.9.1192.20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"2021092307551480000_62.9.1192.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.217463"},{"key":"2021092307551480000_62.9.1192.22","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2008.0584"},{"key":"2021092307551480000_62.9.1192.23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00006231-200005000-00005","article-title":"No-carrier-added 123I-MIBG: an initial clinical study in patients with phaeochromocytoma","volume":"21","author":"Owens","year":"2000","journal-title":"Nucl Med Commun."},{"key":"2021092307551480000_62.9.1192.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0715-3"},{"key":"2021092307551480000_62.9.1192.25","first-page":"269","article-title":"Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med."},{"key":"2021092307551480000_62.9.1192.26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01309.x"},{"key":"2021092307551480000_62.9.1192.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0652-6"},{"key":"2021092307551480000_62.9.1192.28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s12149-013-0755-z","article-title":"Prognostic values of initial responses to low-dose 131I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma","volume":"27","author":"Wakabayashi","year":"2013","journal-title":"Ann Nucl Med."},{"key":"2021092307551480000_62.9.1192.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(03)00426-4"},{"key":"2021092307551480000_62.9.1192.30","doi-asserted-by":"crossref","first-page":"E494","DOI":"10.1210\/clinem\/dgz074","article-title":"Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG","volume":"105","author":"Thorpe","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"2021092307551480000_62.9.1192.31","first-page":"100","article-title":"I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy","volume":"54","author":"Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"2021092307551480000_62.9.1192.32","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345807"},{"key":"2021092307551480000_62.9.1192.33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5603\/EP.a2018.0024","article-title":"131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours: a single-centre study","volume":"69","author":"Kotecka-Blicharz","year":"2018","journal-title":"Endokrynol Pol."},{"key":"2021092307551480000_62.9.1192.34","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ14-0211"},{"key":"2021092307551480000_62.9.1192.35","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348026"},{"key":"2021092307551480000_62.9.1192.36","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12341"},{"key":"2021092307551480000_62.9.1192.37","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-2-455"},{"key":"2021092307551480000_62.9.1192.38","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.nucmedbio.2008.06.004","article-title":"Meta-iodobenzyl guanidine for detection and staging of neuroendocrine tumors","volume":"35(suppl 1)","author":"Pryma","year":"2008","journal-title":"Nucl Med Biol."},{"key":"2021092307551480000_62.9.1192.39","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcu208"},{"key":"2021092307551480000_62.9.1192.40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","article-title":"Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience","volume":"33","author":"Shilkrut","year":"2010","journal-title":"Am J Clin Oncol."},{"key":"2021092307551480000_62.9.1192.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.230607"},{"key":"2021092307551480000_62.9.1192.42","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0056"},{"key":"2021092307551480000_62.9.1192.43","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","article-title":"111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med."},{"key":"2021092307551480000_62.9.1192.44","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050476"},{"key":"2021092307551480000_62.9.1192.45","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00259-018-4117-x","article-title":"Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation","volume":"46","author":"Aalbersberg","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021092307551480000_62.9.1192.46","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.192203"},{"key":"2021092307551480000_62.9.1192.47","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bjc.1993.266","article-title":"Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue","volume":"67","author":"Hammond","year":"1993","journal-title":"Br J Cancer."},{"key":"2021092307551480000_62.9.1192.48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/00365517709101835","article-title":"S\u00f8lling K. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids","volume":"37","author":"Mogensen","year":"1977","journal-title":"Scand J Clin Lab Invest."},{"key":"2021092307551480000_62.9.1192.49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12149-014-0843-8","article-title":"Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors","volume":"28","author":"Calais","year":"2014","journal-title":"Ann Nucl Med."},{"key":"2021092307551480000_62.9.1192.50","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2021092307551480000_62.9.1192.51","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1744-x"},{"key":"2021092307551480000_62.9.1192.52","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.116.186841","article-title":"Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive?","volume":"58(suppl 2)","author":"Eberlein","year":"2017","journal-title":"J Nucl Med."},{"key":"2021092307551480000_62.9.1192.53","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0778-1"},{"key":"2021092307551480000_62.9.1192.54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2021092307551480000_62.9.1192.55","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-011-1872-3","article-title":"Clinical significance of 2-F-18 fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of I-131-metaiodobenzylguanidine therapy in malignant phaeochromocytoma","volume":"38","author":"Nakazawa","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021092307551480000_62.9.1192.56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"key":"2021092307551480000_62.9.1192.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2021092307551480000_62.9.1192.58","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate","volume":"46(suppl 1)","author":"Valkema","year":"2005","journal-title":"J Nucl Med."},{"key":"2021092307551480000_62.9.1192.59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and 131I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J Surg Oncol."},{"key":"2021092307551480000_62.9.1192.60","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"2021092307551480000_62.9.1192.61","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5"},{"key":"2021092307551480000_62.9.1192.62","first-page":"1599","article-title":"Effects of therapy with 177Lu-DOTA0,Tyr3 octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med."},{"key":"2021092307551480000_62.9.1192.63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7873"},{"key":"2021092307551480000_62.9.1192.64","first-page":"1521","article-title":"Comparison of 18F-FDG and 68Ga-DOTATATE before and after two cycles of PRRT [abstract]","volume":"60","author":"Lindenberg","year":"2019","journal-title":"J Nucl Med."},{"key":"2021092307551480000_62.9.1192.65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3703"},{"key":"2021092307551480000_62.9.1192.66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.semnuclmed.2016.01.011","article-title":"I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma","volume":"46","author":"Carrasquillo","year":"2016","journal-title":"Semin Nucl Med."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.120.259697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T12:12:59Z","timestamp":1632399179000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.120.259697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,2]]},"published-print":{"date-parts":[[2021,9,1]]}},"alternative-id":["10.2967\/jnumed.120.259697"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.120.259697","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}